Drug
Preladenant clinical trials
Also written SCH 420814 and MK-3814.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses preladenant is read from its arms, and is right about nine times in ten.
Testing it · 12
- Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)CompletedPhase 2Merck Sharp & Dohme LLCNCT00537017Written as Preladenant
- Dyskinesia in Parkinson's Disease (Study P04501)CompletedPhase 2Merck Sharp & Dohme LLCNCT00406029Written as Preladenant
- Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00686699Written as Preladenant
- A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)CompletedPhase 2Merck Sharp & Dohme LLCNCT01294800Written as Preladenant
- Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)CompletedPhase 1Merck Sharp & Dohme LLCNCT00845000Written as SCH 420814 10 mg
- Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00693472Written as Preladenant
- A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01155479Written as Preladenant 2 mg tablet
- A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)CompletedPhase 3Merck Sharp & Dohme LLCNCT01155466Written as Preladenant 2 mg tablet
- An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01215227Written as Preladenant
- A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)CompletedPhase 1Merck Sharp & Dohme LLCNCT01323855Written as Preladenant
- Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)CompletedPhase 3Merck Sharp & Dohme LLCNCT01227265Written as Preladenant
- A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)CompletedPhase 1Merck Sharp & Dohme LLCNCT01465412Written as Preladenant
Given in every arm · 1 — preladenant is usual care beside what is tested
Codes
What other systems call preladenant · ClinicalTrials.gg INT005419
- UNII (FDA) 950O97NUPOPRELADENANTConfirmed FDA, NLM, Wikidata
- Wikidata Q7240024preladenantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76394PreladenantOne source FDA
- DrugBank DB11864One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 950O97NUPO | PRELADENANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7240024 | preladenant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76394 | Preladenant | One source FDA |
| DrugBank | DB11864 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.